To study the prevalence of B type Raf kinase (BRAF) mutations, and to evaluate the ultrasonographic and clinicopathological features associated with thyroid cytology of indeterminate nodules.
INTRODUCTION

Ultrasonography-guided fine needle aspiration (US-FNA)
is the most accurate method for distinguishing malignant thyroid nodules from benign nodules. It is, however, an operator- (Fig. 1) .
Definition of Indeterminate Cytology Cases
Indeterminate cytology was defined as atypia of undetermined significance; these specimens contained cells (follicular, lymphoid, or other) with insufficient architectural and/or nuclear atypia to be classified as suspicious for a follicular neoplasm, suspicious for malignancy, or malignant according to the Bethesda system for reporting thyroid cytopathology (14) . Most cases included focal features suggestive of papillary carcinoma including nuclear grooves, enlarged nuclei with pale chromatin, and alterations in the nuclear contour and shape in an otherwise predominantly benign-appearing sample. Some samples with preparation artifacts such as air-drying artifacts or clotting artifacts were included when enough follicular cells were present. The diagnostic correlation was and testing feasibility in the pre-operative stage (7-10). A cytology-based BRAF mutation test can give certain clinical information, but not all papillary thyroid cancer (PTC) cases carry BRAF mutations. Thus, the mutation alone is not sufficient to diagnose PTC. Since the prevalence of BRAF V600E is reportedly much higher (73-84%) in Korean PTC patients (11, 12) compared to PTC patients in western countries (29-69%) (13), we hypothesized that a BRAF mutation test in conjunction with a cytology exam would help identify the true status of thyroid nodules diagnosed as indeterminate on fine needle aspiration cytology (FNAC). Therefore, we assessed the prevalence of the BRAF mutation and ultrasonographic and clinicopathologic features of thyroid nodules with indeterminate cytology.
MATERIALS AND METHODS
Patient Selection
This retrospective study was approved by the institutional review board at our institution. The patient dataset was reviewed to specifically identify individuals with preoperative FNA demonstrating cytologic findings that were indeterminate for malignancy. We studied patients who presented between January 2008 and December 2009 at our institution. 
RESULTS
Analysis of Data for Patients Who Underwent a BRAF Mutation Test
Among the 44 patients, only 35 patient slides were available for the BRAF mutation test because we excluded 9 slides that restricted to cases in which the cytology was reported as indeterminate within a six-month period preceding the histology report. We reviewed and analyzed the features of specimens diagnosed as indeterminate on preoperative FNAC and correlated the results with a cytology-based BRAF mutation analysis and with a final histologic diagnosis.
US-Guided FNA
For all patients examined, US images were obtained with a LOGIQ 9 ultrasound scanner (GE Medical Systems, Milwaukee, WI, USA), which was used for guidance with broad band high-frequency (7-15 MHz) linear transducers. US-FNA was performed on solitary or multiple thyroid nodules by a single board-certified radiologist using a 22-gauge needle attached to a 10-mL syringe with 2-4 passes through the target lesion.
The specimens were smeared on slides, fixed immediately in 95% ethanol, and stained using the Papanicolaou method. All the nodules selected for FNA, regardless of size, had at least one malignant ultrasonographic finding such as marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, or a nonparallel shape. Repeated FNA was performed at two-month intervals when the cytology results were indeterminate or non-diagnostic due to scanty cellularity.
DNA Isolation from FNA Samples
A pathologist reviewed all the slides, chose one for each case that contained the most atypical cells, and extracted DNA using the slide scrape lysate method and a single-edged razor 
Clinicopathologic Features of the Indeterminate Cytology Cases
No significant statistical differences were found for sex, patient age, or lesion size between the group with the mutation and the group without the BRAF V600E mutation. Lymphovascular invasion or lymph node metastasis accompanying PTC was independent of whether the PTC was positive or negative for the BRAF V600E mutation, but a significantly higher frequency of extrathyroidal extension was noted in PTCs positive for the BRAF mutation ( Table 1 ).
The clinicopathological features of the nodules with a corresponding BRAF V600E mutation test and final histology are listed in Table 2 . PTC with the BRAF V600E mutation was more frequently found in women than in men (82.4% vs. 17.6%, respectively Note.-BRAF = B type Raf kinase, ETE = extrathyroidal extension, FNA = fine needle aspiration, LNM = lymph node metastasis, LVI = lymphovascular invasion surgery. In our study, we found that BRAF mutation analysis fined as being equal to or less than 1.0 cm, while only 5 cases had a PTC larger than 1.0 cm. Extrathyroidal extension was identified in 8 patients (47%) -two PTCs and six PMCs. All cases (n = 3) of lymph node metastasis were present with PMC.
Ultrasonographic Features of Nodules with Persistent
Indeterminate Cytology
The ultrasonographic features of nodules with a corresponding BRAF mutation test and final histology are summarized in Table 3 . All cases of indeterminate cytology that proved to be malignant at final histopathology were spongiform in appearance with an irregular margin (n = 6), peripheral rim calcifica- A 58-year-old woman with a papillary thyroid carcinoma positive for the BRAF V600E mutation. Note the thyroid nodule has an irregular margin with hypoechoic lesion through the disrupted peripheral rim calcification, suggestive of a malignant nodule. However, most of the lesion cannot be characterized, including the internal echogenicity and presence of internal microcalcification, because of the strong posterior shadow accompanying the dense rim calcification. Note.-BRAF = B type Raf kinase 
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The prevalence of the BRAF mutation in thyroid nodules with indeterminate cytological diagnoses is reported to range from 8% to 16% of cases (7-10, 15-18). In our study, we noted BRAF mutations in more than 40% of cases and we presume that this is due to nodules we selected having more than one ultrasonographic feature suspicious for malignancy. Of the nodules we encountered that were less than 1 cm in size (n = the lack of DNA. In our study, we excluded all the slides that showed inadequate cytology due to scanty cellularity (probably due to insufficient levels of tumor DNA in nucleic acid preparations). We were able to test for BRAF mutations using a direct pyrosequencing method in 35 of 44 (80%) paraffinembedded FNA tissue samples. tive FNAs leading to a surgical procedure, despite the fact that the cytology results really gave no specific information in terms of whether the nodule was suspected to be malignant or benign.
Also, thyroid malignancies with the BRAF V600E mutation had higher rates of extrathyroidal extension and a higher stage than those without the mutation; however, the number of selected patients was too small to prove the relationship between BRAF V600E mutation and clinicopathologic features. Furthermore, routine lateral neck dissections were not performed in all cases, and follow-up exams were not performed.
Because the prevalence of the BRAF V600E mutation was very high for PTC cases, the results of a previous report (29) indicate that pre-operative molecular detection of the BRAF mutation would have helped to establish the diagnosis and make therapeutic decisions. In our study, DNA sequencing analysis to detect the BRAF V600E mutation had a positive predictive value of 100%, thus ensuring the diagnosis of PTC when the BRAF V600E mutation was detected on the pre-operative examination of the FNAB thyroid nodule specimens. 
